Results 221 to 230 of about 86,323 (286)

Cooperative nucleic acid binding by Poly ADP-ribose polymerase 1. [PDF]

Sci Rep
Melikishvili M, Fried MG, Fondufe-Mittendorf YN.   +2 more
europepmc   +1 more source

Therapy-related myeloid neoplasms in Korean patients with ovarian or primary peritoneal cancer treated with poly(ADP-ribose) polymerase inhibitors. [PDF]

Transl Cancer Res
Jang YJ, Kim H, Ryu SY, Kim MH, Kim BJ, Jung HJ, Kang J, Yang SH, Na II, Lee HR, Kang HJ.   +10 more
europepmc   +1 more source

Genetic Implications for Cancer Management: The Changing Landscape of Poly (ADP-ribose) Polymerase Inhibitor Indications in the Treatment of Ovarian Cancer. [PDF]

Clin Obstet Gynecol
Walsh C.
europepmc   +1 more source

Are Poly (ADP-Ribose) Polymerase Inhibitors Safe in Paraneoplastic Dermatomyositis due to High-Grade Serous Carcinoma of the Ovary? A Case Report and a Review of the Literature. [PDF]

Case Rep Oncol
Koheeallee K, Sarivalasis A.
europepmc   +1 more source

Erratum: DTX3L E3 ligase targets p53 for degradation at poly ADP-ribose polymerase-associated DNA damage sites. [PDF]

iScience
Yan Q, Ding J, Khan SJ, Lawton LN, Shipp MA.   +4 more
europepmc   +1 more source

Distribution of pamiparib, a novel inhibitor of poly(ADP-ribose)-polymerase (PARP), in tumor tissue analyzed by multimodal imaging. [PDF]

J Pharm Anal
Morosi L, Timo S, Amodeo R, Lupi M, Meroni M, Bello E, Frapolli R, Martano G, D'Incalci M.   +8 more
europepmc   +1 more source

Poly (ADP-ribose) Polymerase Inhibitor Resistance Driven by Emergence of Polyclonal Mutations With Convergent Evolution: A Molecular Tumor Board Discussion. [PDF]

JCO Precis Oncol
Fatteh M, Wehr J, Karaindrou K, Xian RR, Gocke C, Lin MT, Petry D, Visvanathan K, Couzi R, Santa Maria C, Stearns V, Tao JJ, Anagnostou V, Canzoniero JV, and the Johns Hopkins Molecular Tumor Board, Johns Hopkins Molecular Tumor Board.   +15 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Poly(ADP-ribose) polymerase inhibition: past, present and future

Nature Reviews Drug Discovery, 2020
Nicola J Curtin, Csaba Szabo
exaly   +2 more sources

Poly(ADP-Ribose) Polymerase Inhibitors

Current Medicinal Chemistry, 2003
Poly(ADP-ribose) polymerase-1 (PARP-1) is the principal member of the PARP enzyme family consisting of PARP-1 and several recently identified novel poly(ADP-ribosyl)ating enzymes. PARP-1 functions as a DNA damage sensor and signalling molecule. Upon binding to DNA breaks, activated PARP cleaves NAD(+) into nicotinamide and ADP-ribose and polymerizes ...
Garry J, Southan, Csaba, Szabó
openaire   +2 more sources

Trapping Poly(ADP-Ribose) Polymerase

The Journal of Pharmacology and Experimental Therapeutics, 2015
Recent findings indicate that a major mechanism by which poly(ADP-ribose) polymerase (PARP) inhibitors kill cancer cells is by trapping PARP1 and PARP2 to the sites of DNA damage. The PARP enzyme-inhibitor complex "locks" onto damaged DNA and prevents DNA repair, replication, and transcription, leading to cell death.
Yuqiao, Shen, Mika, Aoyagi-Scharber, Bing, Wang   +2 more
openaire   +2 more sources